Gut microbiota (the ecological community of microorganisms that live in the gut) may be an important environmental risk factor for multiple sclerosis (MS). This suggests that strategies to correct the imbalance in the normal intestinal flora, also known as microbial dysbiosis may help treat or event prevent MS.
Stem cell treatment has been proven to both halt MS clinical relapses and the development of new brain lesions over a prolonged period, according to the results of a new study. The results, achieved in 23 out of 24 patients in a Phase 2 clinical trial, were published in…
A bicycle specially designed to mimic the symptoms of multiple sclerosis (MS) now has its own owner’s manual, and the group behind the bike’s creation is inviting anyone interested to build their own experience of the spasticity and physical discomforts so well-known to people with the disease. The manual, which…
Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment for primary progressive multiple sclerosis (PPMS), Breakthrough Therapy Designation based on positive Phase 3 clinical trial results showing that ocrelizumab significantly reduced disability progression and other disease activity markers compared to placebo. The FDA designation is…
In a special feature published in the journal American Health & Drug Benefits, authors Stanton R. Mehr, President of SM Health Communications, and Marj P. Zimmerman, President of RxDirections, discuss the many unmet medical needs multiple sclerosis (MS) patients still face in dealing with the…
An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease. The Coral Gables MS Exchange event will be held from 10:30 a.m. to 2:15 p.m. on…
A research team from Oxford Brookes University is being given a £70,000 ($107,000) grant to analyze whether dark chocolate can help ease symptoms of multiple sclerosis (MS). The Multiple Sclerosis Society (MS Society) will fund the study. The goal of the project, according to a press release, is to investigate if a…
In a recent study entitled “Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,” researchers investigated whether sulfasalazine treatment, an anti-inflammatory and immune-modulating drug, could promote remyelination of axons in an organism model of demyelination diseases such as multiple sclerosis (MS). The study was published in the…
Two upcoming, free events for members of the multiple sclerosis community are to be held during the next few weeks at Coral Gables, Florida, and San Antonio, Texas, respectively. Sponsored by the pharmaceutical firm Genzyme, these interactive events will provide opportunities for people with MS and members of the MS community…
Psychiatric comorbidity is common in patients with multiple sclerosis (MS), and affects the MS community more frequently than a matched control population, although the incidence is stable over time, according to recent findings of a study published in the journal Neurology, the Official Journal of the American Academy…
Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) — held in Barcelona October 7–10, 2015 — supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…
In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…
Among the different therapeutic approaches being explored for treating MS, adult stem cell therapy continues to be one of the most discussed and anticipated in the MS community. “Stem cells” — the common term for undifferentiated, self-renewing proliferating cells — are currently being investigated for their ability to treat patients in a wide range of disease…
Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 – 10, 2015). The first parallel session was entitled “Will…
Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled “Free Communications” took place. In the first session, several topics related to multiple…
A Satellite Symposia entitled “Discovering a new world in MS” presented by Teva Neuroscience was held yesterday, October 8 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) currently taking place in Barcelona, Spain, October 7 – 10, 2015. Dr. Omar Khan from the…
A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…
Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D level–related factors,” appeared October 7, 2015 in the journal Neurology.
Three “Hot Topic Sessions” on multiple sclerosis will take place this afternoon (17:00 – 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 – 10. The first session is entitled…
Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRA® (dalfampridine) Extended Release Tablets (10 mg) at this year’s 31st Congress of the European Committee for Treatment and Research in…
A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe and offers clinical benefits for patients with multiple sclerosis (MS). The study is entitled “High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise…
The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 in Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…
Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapy ocrelizumab as a treatment for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…
Cannabis is a plant that can be used in a wide range of settings such as medical purposes, a source of fiber and oils, or as a recreational drug. Growing evidence has been reported on the clinical benefits of medical marijuana (herbal form) for treating chronic pain. Currently, several countries in the…
In a new study entitled “The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients,” a team of scientists discovered that differences in response to glatiramer acetate therapy among multiple sclerosis (MS) patients is potentially dependent on the presence of reactive brain-specific B…
A study led by researchers from the University of Buffalo recently reported the development of a new method to study brain cell interaction more precisely. The study, published in the journal Nature Communications and entitled “Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral…
A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the clinical benefit of different therapies available for relapsing-remitting multiple sclerosis (RRMS). The study is entitled “Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis” and was led…
An encouraging new analysis reveals that fingolimod is an effective multiple sclerosis (MS) therapy for a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centers. MS is a chronic, progressive neurodegenerative disorder that is the result of an attack on the central nervous system…
Non-profit, MS News and Views (MSVN), which works nationally to increase education and knowledge about multiple sclerosis (MS), has announced the organization of two events during the month of October. For the first time, the organization will host two events with the exact same structure and theme,…
Get regular updates to your inbox.
